16 completed, 6 recruiting, 4 active not recruiting, 4 unknown. 39 Phase 2, 12 Phase 1, 8 Phase 3.
Follow Neuromyelitis Optica: new trials by email Literature Review of Neuromyelitis Optica trials Research Report on Neuromyelitis Optica
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders Nabiximols, Placebo - NMO Spectrum Disorder, Spasticity, Muscle | Phase 2 | Withdrawn | Michael, Levy M.D.,Ph.D. | 2026-12-31 | 2025-07-16 | |
| Safety and Efficacy of BAFFR CART for Relapsed/ Refractory Neuromyelitis Optica Spectrum Disorder Anti-BAFFR CART - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Not yet recruiting | Tianjin Medical University General Hospital | 20 | 2026-12-01 | 2026-10-16 |
| A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease CTX112 - Progressive Multiple Sclerosis (PMS), Neuromyelitis Optica | Phase 1 / Phase 2 | Not yet recruiting | CRISPR Therapeutics | 220 | 2026-11-01 | 2026-10-22 |
| Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder Placebo, IL-2 (interleukin 2) - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 60 | 2026-08-30 | 2026-09-09 |
| Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder Intravenous Methylprednisolone (IVMP), Complement protein C5 inhibitor - Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Active not recruiting | Tianjin Medical University General Hospital | 110 | 2025-09-09 | 2026-06-03 |
| Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder Complement protein C5 inhibitor, IVMP - Neuromyelitis Optica Spectrum Disorder Attack | Phase 2 | Withdrawn | Tianjin Medical University General Hospital | 2025-09-03 | 2025-09-10 | |
| Efgartigimod for the Treatment of Acute Optic Neuritis Efgartigimod Alfa, Placebo - Optic Neuritis | Phase 2 | Recruiting | Anastasia Vishnevetsky, MD, MPH | 20 | 2025-08-12 | 2026-10-28 |
| Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases BAFF-R CART - Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University General Hospital | 27 | 2025-04-10 | 2026-10-16 |
| A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients IMC-002, mycophenolate mofetil, MMF - Neuromyelitis Optica Spectrum Disorder (NMOSD) | Phase 1 / Phase 2 | Unknown | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. | 116 | 2024-10-10 | 2024-08-16 |
| A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) B001, Placebo - Neuromyelitis Optica Spectrum Disorders | Phase 2 / Phase 3 | Recruiting | Shanghai Jiaolian Drug Research and Development Co., Ltd | 132 | 2024-07-17 | 2026-05-05 |
| FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack Efgartigimod Alfa Injection, High-dose intravenous methylprednisolone - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 | Unknown | Tianjin Medical University General Hospital | 63 | 2024-07-05 | 2024-07-11 |
| Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder Inebilizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 | Recruiting | Amgen | 15 | 2023-07-03 | 2025-12-05 |
| A Study to Evaluate the Efficacy and Safety of JYP0061 in Patients With Acute Neuromyelitis Spectrum Disease (NMOSD) JYP0061, Intravenous Glucocorticoids, Oral Glucocorticoids - Neuromyelitis Optica Spectrum Disorders | Phase 2 | Recruiting | Guangzhou JOYO Pharma Co., Ltd | 35 | 2023-05-24 | 2024-11-20 |
| Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) Mitoxantrone Hydrochloride Liposome Injection - Neuromyelitis Optica Spectrum Disorder | Phase 2 | Completed | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 46 | 2022-11-28 | 2024-08-07 |
| Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders Daratumumab, Placebo - Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Tianjin Medical University General Hospital | 135 | 2022-11-01 | 2025-03-30 |
| Ofatumumab in AQP4-IgG Seropositive NMOSD Ofatumumab - Neuromyelitis Optica Spectrum Disorder | Phase 1 / Phase 2 | Recruiting | Tang-Du Hospital | 5 | 2022-06-28 | 2026-01-30 |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD Ravulizumab - Neuromyelitis Optica Spectrum Disorder | Phase 2 / Phase 3 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 12 | 2022-06-23 | 2026-06-24 |
| An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult Patients zanubrutinib - Neuromyelitis Optica | Phase 2 | Terminated | Xuanwu Hospital, Beijing | 6 | 2022-05-07 | 2026-04-27 |
| Efficacy and Safety of Belimumab in Neuromyelitis Optica Spectrum Disorders Belimumab - NMO Spectrum Disorder | Phase 1 / Phase 2 | Completed | Tianjin Medical University General Hospital | 14 | 2021-12-12 | 2024-10-16 |
| High Frequency Impulse Therapy for Neuropathic Pain in NMOSD High Frequency Impulse Therapy, High Frequency Impulse Therapy - Sham - Neuromyelitis Optica | Phase 2 | Completed | Massachusetts General Hospital | 46 | 2021-06-07 | 2025-04-30 |
Showing 20 of 39. Sign in to see all of them.
Demyelinating Diseases (3) · Autoimmune Diseases of the Nervous System (2) · Multiple Sclerosis (2) · Multiple Sclerosis, Chronic Progressive (2) · Myasthenia Gravis (2) · Myelitis, Transverse (2) · Optic Neuritis (2) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (2) · Stiff-Person Syndrome (2) · Autoimmune Diseases (1) · Diffuse Cerebral Sclerosis of Schilder (1) · Lambert-Eaton Myasthenic Syndrome (1) · Marijuana Abuse (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Cranial Nerve Diseases (39) · Demyelinating Autoimmune Diseases, CNS (39) · Eye Diseases (39) · Immune System Diseases (39) · Nervous System Diseases (39) · Optic Nerve Diseases (39) · Autoimmune Diseases (38) · Autoimmune Diseases of the Nervous System (37) · Myelitis, Transverse (37) · Optic Neuritis (37) · Demyelinating Diseases (36) · Pathological Conditions, Signs and Symptoms (6) · Central Nervous System Diseases (5) · Disease Attributes (5) · Pathologic Processes (5)
Methylprednisolone (4) · eculizumab (4) · Antilymphocyte Serum (3) · Rituximab (3) · thymoglobulin (3) · Azathioprine (2) · Cyclophosphamide (2) · Filgrastim (2) · Granulocyte Colony-Stimulating Factor (2) · Immunoglobulins, Intravenous (2) · Mesna (2) · Methylprednisolone Acetate (2) · Methylprednisolone Hemisuccinate (2) · Prednisone (2) · efgartigimod alfa (2)
Tianjin Medical University General Hospital (10) · Alexion Pharmaceuticals, Inc. (2) · Northwestern University (2) · Amgen (1) · Anastasia Vishnevetsky, MD, MPH (1) · CRISPR Therapeutics (1) · CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (1) · Fred Hutchinson Cancer Center (1) · Fu-Dong Shi (1) · Guangzhou JOYO Pharma Co., Ltd (1) · Icahn School of Medicine at Mount Sinai (1) · ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. (1) · Isfahan University of Medical Sciences (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1)
China (16) · United States (14) · Canada (6) · Spain (5) · Japan (4) · Germany (3) · Italy (3) · Poland (3) · South Korea (3) · France (2) · Hungary (2) · Russia (2) · Serbia (2) · Turkey (Türkiye) (2) · Argentina (1)
Fu-Dong Shi, MD,PhD (3) · Michael Levy, MD, PhD (3) · Richard Burt, MD (2) · Anastasia Vishnevetsky, MD, MPH (1) · Anastasia Vishnevetsky, MD, PhD (1) · Ilana Katz Sand, MD (1) · Jan Storek, MD,PhD (1) · Jodie M Burton, MD,MSc,FRCPC (1) · Jun Guo, M.D. (1) · Junwei Hao, MD (1) · Leona Holmberg (1) · Qiang Liu, M.D.,Ph.D (1)
PMID 23623397, PMID 23764350, PMID 26083135, PMID 26666258, PMID 28831548, PMID 31495497, PMID 32333897, PMID 33538237, PMID 33724534, PMID 33771837, PMID 35158461, PMID 36370634, PMID 37221052, PMID 38760098, PMID 39222408, PMID 39651334
2008 (1), 2014 (1), 2019 (1), 2023 (1)